Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

Older men with high testosterone levels more likely to have heart attacks

A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

New asthma therapy shows promise for patients who do not respond to steroid treatments

A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Olive oil, Mediterranean diet modify expression of atherosclerosis-related genes

Everyone knows olive oil and a Mediterranean diet are associated with a lower risk for cardiovascular disease, but a new research report published in the July 2010 print issue of the FASEB Journal offers a surprising reason why: These foods change how genes associated with atherosclerosis function.

1 Jul 2010

Researchers to study interventional endovascular therapy on symptoms and progression of MS

Buffalo medical researchers led by a team from the University at Buffalo Department of Neurosurgery, will embark on a landmark prospective randomized double-blinded study to test the safety and efficacy of interventional endovascular therapy -- dubbed "liberation treatment" -- on the symptoms and progression of Multiple Sclerosis.

1 Jul 2010

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Biospherics Incorporated, has signed a license agreement with the University of Kentucky Research Foundation (UKRF).

1 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

Importance of cell-cell communication in ischaemia

A team from the Bristol Heart Institute have investigated the importance of cell-cell communication in regulating the formation of new blood vessels following the restriction in blood supply to the heart or back leg in mice.

29 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

Statins does not reduce death risk in high-risk individuals without heart disease

A meta-analysis of previously published studies finds no evidence that statins are associated with a reduced risk of death among individuals at risk for but with no history of cardiovascular disease, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals

29 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

New research suggests resveratrol may inhibit pathogenic blood vessel formation

Current research suggests that resveratrol, a naturally occurring compound found in red wine, grapes, blueberries, peanuts, and other plants, inhibits pathogenic new blood vessel growth.

25 Jun 2010

Blood flow disturbances in artery determine appearance of atherosclerosis: Study

A new animal model of atherosclerosis has allowed researchers to identify a host of genes turned on or off during the initial stages of the process, before a plaque appears in the affected blood vessel.

24 Jun 2010

START proteins could help treat cholesterol build-up in arteries: Report

A newly discovered group of proteins could help treat cholesterol build-up in arteries. This build-up leads to atherosclerosis or 'hardening of the arteries', and the resulting condition, coronary heart disease, kills an estimated 124,000 each year in England and Wales.

23 Jun 2010

Corgenix receives new European patent for AtherOx technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today the issuance of one new European patent for the company's AtherOx® (oxLDL/B2GPI) technology and the publication of an important clinical trial studying oxLDL/B2GPI levels in patients with acute coronary syndrome (ACS).

23 Jun 2010

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology. The data showed that mice treated with XOMA 052 both prophylactically and therapeutically experienced improvement in measures associated with diabetes and cardiovascular disease including reduction in glycosylated hemoglobin levels, improvement in glucose control, improved beta-cell survival and function, and a reduction in total cholesterol without reduction in high density lipoprotein.

23 Jun 2010

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review.

23 Jun 2010

Beneficial effects of LifeVantage's Protandim on DMD mouse model published in Journal of Dietary Supplements

LifeVantage Corporation, the maker of Protandim®, a patented, science-based solution to oxidative stress, announced today that a peer-reviewed manuscript was published in the Journal of Dietary Supplements examining the beneficial effects of Protandim® on a mouse model of Duchenne Muscular Dystrophy (DMD), an X-linked inherited disease affecting one in 3,500 males.

22 Jun 2010

TransGenRx to produce protein-based therapeutics to support Esperion's research on HDL therapies

Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that TransGenRx, a global leader in transgenic technology, will produce protein-based therapeutics to be used in the company's research efforts targeting HDL therapies for the treatment of cardio-metabolic disease.

22 Jun 2010

Women who experience early menopause may have cardiovascular disease later in life: Study

Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Cerenis Therapeutics SA, a privately held biopharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, today announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations) at the 78th European Atherosclerosis Society Congress on June 20-23 in Hamburg, Germany.

21 Jun 2010

Atherosclerosis News and Research

Further Reading

Older men with high testosterone levels more likely to have heart attacks

New asthma therapy shows promise for patients who do not respond to steroid treatments

Olive oil, Mediterranean diet modify expression of atherosclerosis-related genes

Researchers to study interventional endovascular therapy on symptoms and progression of MS

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

Importance of cell-cell communication in ischaemia

BBD reports analyze effectiveness and safety of statin use

Statins does not reduce death risk in high-risk individuals without heart disease

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

New research suggests resveratrol may inhibit pathogenic blood vessel formation

Blood flow disturbances in artery determine appearance of atherosclerosis: Study

START proteins could help treat cholesterol build-up in arteries: Report

Corgenix receives new European patent for AtherOx technology

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

Genentech's Lucentis for treatment of macular edema following RVO receives FDA approval

Beneficial effects of LifeVantage's Protandim on DMD mouse model published in Journal of Dietary Supplements

TransGenRx to produce protein-based therapeutics to support Esperion's research on HDL therapies

Women who experience early menopause may have cardiovascular disease later in life: Study

Results of two clinical proof-of-concept studies for CER-627 program to be presented at EAS Congress 2010

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News